Pharmacotherapy in the Era of Pandemics: Latest Advances and Prospects
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Optimization".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 482
Special Issue Editors
Interests: clinical epidemiology; infectious diseases; cancer; critical care
Interests: pharmacotherapy; pharmacoeconomics; pharmacovigilance; side effects; drug reactions
Interests: infectious diseases; pharmacovigilance; COVID-19 pandemic; pharmacotherapy; biotechnology drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Medications should not be considered as static elements or isolated from the physiological phenomena of the human body or their interaction with other medications. They are dynamic tools, with effects that can be modified by multiple factors and whose use must be balanced to optimize the therapeutic objectives sought and to avoid unwanted effects. Additionally, their use should also be supervised by specialists.
These are difficult times, times in which the emergence of pathogens potentially capable of spreading to produce pandemics makes the sound of war drums, in which medicines are invaluable and essential allies against those tiny beings that strive to circumvent the mechanisms of action of our squalid arsenal. In essence, drugs can act both at the level of prevention and treatment. The sudden emergence of unknown pathogens capable of producing diseases that we are not capable of curing or even alleviating at the time we detect them undoubtedly forces us to investigate to promote the development of these types of drugs. Leaving the research for the moment in which the urgency of the unknown invades us, as we have seen with COVID, is very expensive in terms of health. Additionally, investment in One Health should be mandatory, because most of the consequences that we observe in human health are derived from inaction at other levels.
In this Special Issue, all the papers will present research on drugs used in emerging infectious or non-infectious diseases, their mechanisms of action, interaction with other drugs or repositioning of drugs not used for their intended use in these diseases.
Dr. Antonio Gutiérrez-Pizarraya
Dr. Dorota Kopciuch
Dr. Anna Paczkowska
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pandemic
- epidemiology
- bacteria
- virus
- drug–drug interactions
- repurposing
- clinical trials
- infectious diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
